Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice.

Schwarz P, Body JJ, Cáp J, Hofbauer LC, Farouk M, Gessl A, Kuhn JM, Marcocci C, Mattin C, Muñoz Torres M, Payer J, Van De Ven A, Yavropoulou M, Selby P.

Eur J Endocrinol. 2014 Dec;171(6):727-35. doi: 10.1530/EJE-14-0355. Epub 2014 Sep 20.

2.

Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study.

Chiroli S, Mattin C, Belozeroff V, Perrault L, Mitchell D, Gioni I.

BMC Nephrol. 2012 Oct 29;13:140. doi: 10.1186/1471-2369-13-140.

3.

Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?

Frazão JM, Braun J, Messa P, Dehmel B, Mattin C, Wilkie M.

BMC Nephrol. 2012 Aug 3;13:76. doi: 10.1186/1471-2369-13-76.

4.

Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials.

Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Hörl WH, Mattin C, Praml C, Wilkie M.

Clin Nephrol. 2007 Mar;67(3):140-8.

PMID:
17390738

Supplemental Content

Loading ...
Write to the Help Desk